A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation

A study of five patients

V. Brazzelli, F. Prestinari, T. Barbagallo, C. Rona, E. Orlandi, F. Passamonti, F. Locatelli, M. Zecca, S. Villani, G. Borroni

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Imatinib mesylate (IM), the first-line treatment of chronic myeloid leukaemia (CML), is a tyrosine kinase inhibitor that targets those proteins involved in BCR-ABL signal transduction in CML, c-kit (KIT) and platelet-derived growth-factor (PDGFR) receptor. The use of IM has been associated with cutaneous reactions. In the last 2 years numerous studies have focused the attention on hypopigmentations, depigmentations and photosensitivity developing after the initiation of IM therapy. Objective: The aim of this study is to evaluate the effects of IM therapy on the skin pigmentation of five patients affected by CML. Methods: Skin pigmentation measurements were performed with a Minolta CR-200 Chromameter. Results: All the studied patients show the gradual lightening of the skin on unexposed areas over the treatment with IM. In particular, this explorative colorimetric study indicates the association between IM and skin depigmentation with a significant increase of luminance value (L*) (P = 0.001) and a significant decrease of the pigmentation value (b*) (P = 0.028). Conclusion: Even if we do not know the clinical significance of the skin depigmentation caused by IM, the regulatory role of KIT and its ligand stem cell factor in melanocyte development and survival seems to suggest an objective mechanism of action for IM in the pathogenesis of this cutaneous depigmentation.

Original languageEnglish
Pages (from-to)384-387
Number of pages4
JournalJournal of the European Academy of Dermatology and Venereology
Volume21
Issue number3
DOIs
Publication statusPublished - Mar 2007

Fingerprint

Skin Pigmentation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Skin
Hypopigmentation
Platelet-Derived Growth Factor Receptors
Stem Cell Factor
Imatinib Mesylate
Melanocytes
Pigmentation
Therapeutics
Protein-Tyrosine Kinases
Signal Transduction
Ligands
Survival

Keywords

  • Chronic myeloid leukaemia
  • Colorimetry
  • Hypopigmentation
  • Imatinib mesylate

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation : A study of five patients. / Brazzelli, V.; Prestinari, F.; Barbagallo, T.; Rona, C.; Orlandi, E.; Passamonti, F.; Locatelli, F.; Zecca, M.; Villani, S.; Borroni, G.

In: Journal of the European Academy of Dermatology and Venereology, Vol. 21, No. 3, 03.2007, p. 384-387.

Research output: Contribution to journalArticle

@article{1088639652ea49208fc6efd1b90eee3c,
title = "A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: A study of five patients",
abstract = "Background: Imatinib mesylate (IM), the first-line treatment of chronic myeloid leukaemia (CML), is a tyrosine kinase inhibitor that targets those proteins involved in BCR-ABL signal transduction in CML, c-kit (KIT) and platelet-derived growth-factor (PDGFR) receptor. The use of IM has been associated with cutaneous reactions. In the last 2 years numerous studies have focused the attention on hypopigmentations, depigmentations and photosensitivity developing after the initiation of IM therapy. Objective: The aim of this study is to evaluate the effects of IM therapy on the skin pigmentation of five patients affected by CML. Methods: Skin pigmentation measurements were performed with a Minolta CR-200 Chromameter. Results: All the studied patients show the gradual lightening of the skin on unexposed areas over the treatment with IM. In particular, this explorative colorimetric study indicates the association between IM and skin depigmentation with a significant increase of luminance value (L*) (P = 0.001) and a significant decrease of the pigmentation value (b*) (P = 0.028). Conclusion: Even if we do not know the clinical significance of the skin depigmentation caused by IM, the regulatory role of KIT and its ligand stem cell factor in melanocyte development and survival seems to suggest an objective mechanism of action for IM in the pathogenesis of this cutaneous depigmentation.",
keywords = "Chronic myeloid leukaemia, Colorimetry, Hypopigmentation, Imatinib mesylate",
author = "V. Brazzelli and F. Prestinari and T. Barbagallo and C. Rona and E. Orlandi and F. Passamonti and F. Locatelli and M. Zecca and S. Villani and G. Borroni",
year = "2007",
month = "3",
doi = "10.1111/j.1468-3083.2006.01981.x",
language = "English",
volume = "21",
pages = "384--387",
journal = "Journal of the European Academy of Dermatology and Venereology",
issn = "0926-9959",
publisher = "wiley",
number = "3",

}

TY - JOUR

T1 - A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation

T2 - A study of five patients

AU - Brazzelli, V.

AU - Prestinari, F.

AU - Barbagallo, T.

AU - Rona, C.

AU - Orlandi, E.

AU - Passamonti, F.

AU - Locatelli, F.

AU - Zecca, M.

AU - Villani, S.

AU - Borroni, G.

PY - 2007/3

Y1 - 2007/3

N2 - Background: Imatinib mesylate (IM), the first-line treatment of chronic myeloid leukaemia (CML), is a tyrosine kinase inhibitor that targets those proteins involved in BCR-ABL signal transduction in CML, c-kit (KIT) and platelet-derived growth-factor (PDGFR) receptor. The use of IM has been associated with cutaneous reactions. In the last 2 years numerous studies have focused the attention on hypopigmentations, depigmentations and photosensitivity developing after the initiation of IM therapy. Objective: The aim of this study is to evaluate the effects of IM therapy on the skin pigmentation of five patients affected by CML. Methods: Skin pigmentation measurements were performed with a Minolta CR-200 Chromameter. Results: All the studied patients show the gradual lightening of the skin on unexposed areas over the treatment with IM. In particular, this explorative colorimetric study indicates the association between IM and skin depigmentation with a significant increase of luminance value (L*) (P = 0.001) and a significant decrease of the pigmentation value (b*) (P = 0.028). Conclusion: Even if we do not know the clinical significance of the skin depigmentation caused by IM, the regulatory role of KIT and its ligand stem cell factor in melanocyte development and survival seems to suggest an objective mechanism of action for IM in the pathogenesis of this cutaneous depigmentation.

AB - Background: Imatinib mesylate (IM), the first-line treatment of chronic myeloid leukaemia (CML), is a tyrosine kinase inhibitor that targets those proteins involved in BCR-ABL signal transduction in CML, c-kit (KIT) and platelet-derived growth-factor (PDGFR) receptor. The use of IM has been associated with cutaneous reactions. In the last 2 years numerous studies have focused the attention on hypopigmentations, depigmentations and photosensitivity developing after the initiation of IM therapy. Objective: The aim of this study is to evaluate the effects of IM therapy on the skin pigmentation of five patients affected by CML. Methods: Skin pigmentation measurements were performed with a Minolta CR-200 Chromameter. Results: All the studied patients show the gradual lightening of the skin on unexposed areas over the treatment with IM. In particular, this explorative colorimetric study indicates the association between IM and skin depigmentation with a significant increase of luminance value (L*) (P = 0.001) and a significant decrease of the pigmentation value (b*) (P = 0.028). Conclusion: Even if we do not know the clinical significance of the skin depigmentation caused by IM, the regulatory role of KIT and its ligand stem cell factor in melanocyte development and survival seems to suggest an objective mechanism of action for IM in the pathogenesis of this cutaneous depigmentation.

KW - Chronic myeloid leukaemia

KW - Colorimetry

KW - Hypopigmentation

KW - Imatinib mesylate

UR - http://www.scopus.com/inward/record.url?scp=33847005917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847005917&partnerID=8YFLogxK

U2 - 10.1111/j.1468-3083.2006.01981.x

DO - 10.1111/j.1468-3083.2006.01981.x

M3 - Article

VL - 21

SP - 384

EP - 387

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

IS - 3

ER -